Amit Gupta Sells 15,160 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 15,160 shares of Cardlytics stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $3.92, for a total value of $59,427.20. Following the transaction, the chief executive officer now directly owns 215,494 shares in the company, valued at approximately $844,736.48. The trade was a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Amit Gupta also recently made the following trade(s):

• On Friday, January 3rd, Amit Gupta sold 5,964 shares of Cardlytics stock. The shares were sold at an average price of $3.67, for a total transaction of $21,887.88.

Cardlytics Stock Up 1.3 %

Shares of NASDAQ:CDLX traded up $0.05 during midday trading on Friday, hitting $3.88. 783,034 shares of the stock were exchanged, compared to its average volume of 1,083,136. The business’s fifty day simple moving average is $3.66 and its two-hundred day simple moving average is $4.39. The company has a market capitalization of $197.18 million, a PE ratio of -0.64 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. Cardlytics, Inc. has a 52-week low of $2.76 and a 52-week high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million for the quarter, compared to analyst estimates of $57.77 million. During the same period in the previous year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, research analysts predict that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CDLX. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Evercore ISI started coverage on Cardlytics in a report on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price on the stock. Finally, Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.92.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after purchasing an additional 73,484 shares during the period. Marshall Wace LLP boosted its stake in Cardlytics by 6.8% in the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after purchasing an additional 52,081 shares in the last quarter. RBF Capital LLC increased its position in Cardlytics by 311.9% in the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after acquiring an additional 369,620 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Cardlytics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after buying an additional 11,388 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its position in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after buying an additional 354,474 shares during the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.